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Background: Lung transplantation in adults is an accepted therapeutic option in
end-stage organ disease. In children however, there is ongoing debate on its positive
impact on survival. Together with the scarcity of patients and donor organs, this
has led to a very restrictive use of the procedure, with approximately 80 procedures
performed per year worldwide. We report the results of the ﬁrst twenty years of
pediatric lung transplantation at a single center in Austria.
Methods: Kaplan Meier survival statistics were performed to estimate patient and
organ survival. Pre- and post-transplant parameters were assessed and their inﬂuence
on patient and organ survival evaluated. Univariate tests on the parameters of interest
as well as a stepwise multivariate analysis using Cox regression were performed.
Outcome: A total of 54 transplantations were performed in 43 patients. Mean
estimated patient survival was 104.6 months, 1-year, 5-year and 10-year survival
rates were 78.0%, 62.1% and 40%. Freedom from BOS was found in 94.4% and
47.1% of patients at 1 and 5 years post-transplant. We observed an improvement
of outcome over the years with a 5-year survival of 71.4% in the second decade. A
high rate of successful re-transplantation resulted in prolonged survival in patients
with acute or chronic graft failure after ﬁrst transplantation.
Conclusion: In our collective, we show a mean survival rate after pediatric lung
transplantation of almost ten years, indicating a survival beneﬁt of the procedure.
In future, multicenter analyses are required the deﬁnition of distinct age-associated
aspects of pediatric lung transplantation.
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Objectives: There is conﬂicting evidence of good outcome in cystic ﬁbrosis (CF)
patients with NTM infection undergoing lung transplantation (LTx). We conducted
a study to evaluate the outcomes of all LT×CF patients in Denmark with current
or prior NTM.
Methods: From a recent analysis of all Danish CF patients testing positive for
NTM over the last 19 years, we identiﬁed patients who had undergone LTx. Data
on clinical manifestations, treatment regimens and outcomes were extracted from
patient ﬁles.
Results: Nine patients with NTM infection had undergone LTx between 1997 and
2010. The median age at time of ﬁrst NTM positive sputum sample and LTx was
18 and 29 years, respectively. Five patients were cured of their NTM prior to LTx.
Active disease at the time of LTx was present in four patients with M. abscessus.
Two of these died shortly after LTx due to graf dysfunction. Two acquired deep
surgical wound infections postoperatively; one has been cured after extensive anti-
mycobacterial treatment, while the other still receives treatment for a substernal
abscess. Both remain healthy and all post-LTx BAL samples are negative.
Conclusion: There has previously been a few reports of good clinical outcome after
LTx among CF patients with M. abscessus infection, even when patients failed to
clear infection. We found four patients with active M. abscessus at the time of LTx,
two died of unrelated causes and two had serious complications, but good outcome.
The current study conﬁrms that CF patients with NTM can successfully undergo
LTx. Postoperative complications in the form of deep tissue wound infections can
be expected, but do not rule out good clinical outcome.
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Lung transplantation is a well established treatment for patients with cystic ﬁbrosis
with end-stage lung disease. Some pathogens can affect long term survival in these
patients, although it is not clear whether the same strain persist after lung graft.
The primary goal was to analyse the clonal relatedness of bacterial strains belonging
to the most important species isolated before and after lung transplantation.
Seven patients (5 males and 2 females, median age at transplant 34 years, range
20−42) were studied. The isolates were collected before (median 12 months,
range 9−22) and after (median 12 months, range 2−16) lung transplantation.
Bacterial isolates belonging to different species were collected and identiﬁed using
biochemical commercial tests. Strains isolated from the same patients belonging to
the same species were genotyped by means of Rep-PCR.
Forty-eight isolates were collected: 38 Pseudomonas aeruginosa (Pa), 4 Achromo-
bacter xylosoxidans (Ax), 3 methicillin-resistant Staphylococcus aureus (MRSA)
and 3 Inquilinus limosus (Il). Each species was isolated before and after lung graft.
Pa, MRSA and Il bacterial strains collected from 6 out of 7 patients showed no
variability before and after lung transplantation, demonstrating a clonal relationship.
Only Ax strains from one remaining patient had different ﬁngerprinting.
All patients had the same bacterial species strains before and after transplantation.
Further studies are necessary to evaluate if this persistence affects transplant
outcome. This evidence could clarify the role of bacterial infection in transplant
outcome and thus lead to improved treatment strategies.
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Objectives: Patients with cystic ﬁbrosis (CF) are known to have malabsorption
of lipophilic compounds. This could potentially inﬂuence the uptake of cyclo-
sporine (CsA). The aim of the present study was to analyse blood concentrations
of CsA in relation to drug dosage in lung transplanted (LTx) patients with and
without CF.
Methods: All LTx CF patients in Denmark between 1992–2005, were compared
to an age matched non-CF LTx control group from the same period. Patient data
was collected by retrospective chart review and from a central database. Follow-up
was 24 months. A subanalysis of co-administration of pancreatic enzyme and meal
timing on CsA dosing and concentration was also performed.
Results: 66 patients were included, hereof 36 CF patients and 30 controls. Despite
higher or equal CsA dosing in the CF group, blood concentrations were consistently
lower compared to the control group over the 24-month follow-up (p = 0.0003).
On average, CsA blood concentrations were 67 ng/ml lower in the CF group.
No statistically signiﬁcant association was found between co-administration of
pancreatic enzyme and timing of CsA administration in relation to meals and CsA
concentration (p = 0.8912) or dosage (p = 0.1341).
Conclusion: In this case-control study we found that LTx CF patients had sig-
niﬁcantly lower CsA blood concentrations post-LTx than an age-matched control
group, despite equivalent CsA dosing. This strongly suggests poorer CsA absorption
in CF patients independent of co-administration of pancreatic enzyme and timing
of drugs in relation to meals. We recommend careful monitoring of CsA blood
concentrations to prevent underdosing of CF patients.
